SG/CALL/BRISTOL-MYERS SQUIBB/50/0.1/20.09.24 | Delayed Deutsche Boerse AG 16:09:29 26/06/2024 BST | ||
| 0.041 EUR | +17.14% |
|
| Current month | -14.63% | ||
| 1 month | -5.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 0.041 | +17.14% |
| 25/06/24 | 0.035 | 0.00% |
| 24/06/24 | 0.035 | -5.41% |
| 21/06/24 | 0.037 | -5.13% |
| 20/06/24 | 0.039 | +8.33% |
Delayed Quote Deutsche Boerse AG
Last update June 26, 2024 at 04:09 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SW3VV7 |
| ISIN | DE000SW3VV71 |
| Date issued | 22/09/2023 |
| Strike | 50 $ |
| Maturity | 20/09/2024 (86 Days) |
| Parity | 10 : 1 |
| Emission price | 1.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.13 € |
|---|---|
| Lowest since issue | 0.029 € |
| Spread | 0.01 € |
| Spread % | 20.00% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.19
USD
Average target price
53.19
USD
Spread / Average Target
+26.08%
- Stock Market
- Warrants
- Warrant
